AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05978505
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 nightly doses to commence after surgery.
Trial: NCT06517173
Drug: Y-3 for injection
RxNorm normalized name: Y
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qualified subjects were randomly divided into groups in a 1:1 ratio and received continuous treatment with Y-3 injection (40 mg/dose, qd) or placebo control drug. The treatment was performed 10 times for 10 days.
Trial: NCT06517173
Drug: Placebo control group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qualified subjects were randomly divided into groups in a 1:1 ratio and received continuous treatment with Y-3 injection (40 mg/dose, qd) or placebo control drug. The treatment was performed 10 times for 10 days.
Trial: NCT04922359
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients received 0.075ml/kg of intravenous normal saline during induction of anesthesia and 0.075ml/kg/h for anesthesia maintenance.
Trial: NCT06326684
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The effects of placebo will be determined.
Trial: NCT05584306
Drug: 610 30mg group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 610 30mg subcutaneous (SC) Q4W，8 times
Trial: NCT05584306
Drug: 610 100mg group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 610 100mg subcutaneous (SC) Q4W，8 times
Trial: NCT05584306
Drug: 610 300mg group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 610 300mg subcutaneous (SC) Q4W，8 times
Trial: NCT05914389
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral Capecitabine 1000 mg/m2 twice daily combined with oxaliplatin chemotherapy from Day 1 to Day 14 every 3 weeks and repeat for 4 cycles. The dose reduction protocol for capecitabine-induced toxicity was implemented according to the report in BJC (2018) 118:1322-1328.
Trial: NCT05914389
Drug: Clostridium butyricum
RxNorm normalized name: Clostridium butyricum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clostridium butyricum is treated with Miyarisan 588 powder, 160mg/day (4 packets/day) taken orally for a total of 6 weeks.There have been no reports of adverse reactions for Lactobacillus. There is no predetermined reduction plan.
Trial: NCT05288725
Drug: Corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The corticosteroid is prepared in a 10 ml syringe by combining 1-2 mL Kenalog \[40 mg/dL\], 6-8 mL sterile normal saline, 3-4 mL Ropivicaine 1%.
Trial: NCT06730282
Drug: Danggui Shaoyao San (DSS)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Danggui Shaoyao San is a traditional Chinese medicine (TCM) formula used to regulate blood flow, alleviate pain, and reduce inflammation. Participants in this arm will receive DSS starting 3 to 7 days before menstruation and continue until 3 days after menstruation for two cycles.
Trial: NCT06730282
Drug: Cuscuta Chinensis (Tu Si Zi)
RxNorm normalized name: Cuscuta chinensis seed extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cuscuta Chinensis is a TCM formula traditionally used to nourish kidney essence and improve menstrual health. Participants in this arm will receive Tu Si Zi starting 3 to 7 days before menstruation and continue until 3 days after menstruation for two cycles.
Trial: NCT05850286
Drug: VRD-based Regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bortezomib, Lenalidomide and Dexamethasone
Trial: NCT06730282
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants in this arm will receive a placebo that matches the appearance of the study medications. The placebo will be administered on the same schedule as the active treatments for two menstrual cycles.
Trial: NCT05841238
Drug: LY3502970
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT05037539
Drug: Fentanyl Citrate 50Mcg/Ml Inj_#1
RxNorm normalized name: FENTANYL CITRATE 50MCG/ML INJ_#1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injectable Fentanyl in Sublingual Route 50 mcg
Trial: NCT05660811
Drug: 6 months treatment with a single antiplatelet agent
RxNorm normalized name: Detoxifying agents for antineoplastic treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: continuing single antiplatelet agent up until 6 months
Trial: NCT05786638
Drug: Allergen Immunotherapy Extract
RxNorm normalized name: Allergen immunotherapy extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual subcutaneous allergen immunotherapy
Trial: NCT04819204
Drug: Testosterone gel
RxNorm normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone gel - transdermal application of 5mg/day on Day 7-14 of GnRH antagonist
Trial: NCT05197179
Drug: FB2001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be administered with FB2001 by intravenous (IV) infusion
Trial: NCT00610337
Drug: Cethrin® (BA-210)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative epidural administration during spinal decompression surgery
Trial: NCT04526132
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo diluted to 100 ml with 0.9% sodium chloride injection.Use a micro-injection pump to inject intravenously at a constant speed for 30 min (± 2 min).~One dose at 8h、16h 、24h、32h and 40h after the start of the first dose,the first intravenous infusion was started at the end of the operation (Skin suture completes the last stitch).The drug was given 6 times,3 times/day,once every 8 hours.
Trial: NCT04737889
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Induction Chemotherapy: 3mg/m2, Intravenous administration (pumping for 3h) on day 1 of each 3-week cycle until disease progression/stable disease or unacceptable toxicity develops, up to 6 cycles.
Trial: NCT06719570
Drug: MK-8591A
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed dose combination tablet
Trial: NCT06719570
Drug: Doravine
RxNorm normalized name: doravine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet
Trial: NCT05590117
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo tablets
Trial: NCT05590117
Drug: FOLFOX-6 regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 cycles of FOLFOX-6 regimen
Trial: NCT06556277
Drug: Metyrapone And Hydrocortisone
RxNorm normalized name: Metyrapone
DrugBank: Metyrapone (DB01011)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drug: Metyrapone 250 mg Oral Tablets~During one phase of the study: Metyrapone (pills of 250mg) on full stomach: Day 1 0-1-2, day 2 1-2-2, day 3 3-3-4 day 4 3-3-4 day 5 3-3-4 day 6 3-3-4 day 7 3-0-0~Drug: Hydrocortisone 19,9mg/12mg s.c., pulsatile with a flow rate of 10μl/s~Hydrocortisone will be delivered subcutaneously via a pump in a pulsed fashion with a flow rate of 10μl/s from day 1 to day 6 in a total daily dose of 19.9mg and 12mg on day 7
Trial: NCT06556277
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: Placebo 250 mg Tablets~During another phase of the study: identical looking placebo pills starting Day 1 During one phase of the study: Metyrapone (pills of 250mg) on full stomach: Day 1 0-1-2, day 2 1-2-2, day 3 3-3-4 day 4 3-3-4 day 5 3-3-4 day 6 3-3-4 day 7 3-0-0~Drug: Placebo (0,9% NaCl solution)~Placebo (0,9% NaCl solution) 19.9 mg/d subcutaneously via a pump in a pulsed fashion with a flow rate of 10μl/s from day 1 to day 6 and 12mg on day 7
Trial: NCT06261567
Drug: Biologic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receiving treatment with any biologic treatment for severe asthma which is approved within the UK NHS. These include omalizumab, mepolizumab, reslizumab, benralizumab and/or dupilumab
Trial: NCT05207722
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide: 900 mg/m2 administered IV as part of a 3-day lymphodepletion regimen.
Trial: NCT05487300
Drug: Autonomic testing on and off levodopa
RxNorm normalized name: Off! Explore
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants with Parkinson's disease with and without orthostatic hypotension will undergo standardized autonomic testing on two separate days on levodopa and off levodopa.
Trial: NCT06470373
Drug: Eylea® Solution for intravitreal injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administer 2 mg/eye (50 uL/eye) per dose of the IP via IVT to the subjects' study eye
Trial: NCT06039566
Drug: IV N-acetylcysteine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) 150 mg/kg (Max dose 15,000 mg) through an IV that will run for 60 minutes at the start of the procedure
Trial: NCT06039566
Drug: IV Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 0 mg/kg (placebo: 0.45% NaCl or D5W) through an IV that will run for 60 minutes at the start of the procedure.
Trial: NCT05636306
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A volume of 0.9% normal saline matching the volume required for a weight-based dosing of NoNO-42, administered as a single 10±1 minute intravenous infusion.
Trial: NCT05057819
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment naive patients with bariatric bypass surgery will be given oral placebo once daily for 20 days
Trial: NCT06081959
Drug: SKB264
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion on day 1 and Day 15 of each 28 day cycle
Trial: NCT06081959
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000-1250 mg/m2, po, bid, from day 1 to Day 15 of each 21 day cycle
Trial: NCT05691959
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients randomized to placebo group will receive Normal Saline 50ml IV.
Trial: NCT05983939
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single and multiple ascending oral doses of matching placebo tablets.
Trial: NCT05691959
Drug: Calcium
RxNorm normalized name: Calcium
DrugBank: Calcium sulfate (DB15533)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients randomized to the study group will receive Calcium 2gm in Normal Saline 50ml IV.
Trial: NCT05436678
Drug: Celecoxib 200mg
RxNorm normalized name: CELECOXIB 200MG CAP
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Celecoxib
Trial: NCT05764746
Drug: Artemether-lumefantrine
RxNorm normalized name: artemether-lumefantrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This will be the comparator arm as standard treatment, where only AL will be given twice a day for three days then placebo for three days
Trial: NCT04785261
Drug: TCM Formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6.0g Chi-Ju-Di-Huang-Wan plus 6.0g Jia-Wei-Xiao-Yao-San, 6.0g twice daily for 12 weeks.
Trial: NCT05459974
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pill once daily for 30 days after the atrial fibrillation ablation
Trial: NCT06439524
Drug: 40 mg relugolix, 1 mg estradiol, 0.5 mg norethindrone acetate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: if randomized to study drug, participants will take one tablet Rel-CT daily following excisional surgery for endometriosis
Trial: NCT06263517
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For Arm 4, patients will be treated with Placebo 2 ml from Baseline to Week 3
Trial: NCT06648720
Drug: DAPT de-escalation
RxNorm normalized name: sangre de grado
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in this group will receive DAPT (aspirin and a P2Y12 inhibitor) for 1 month, followed by monotherapy with a P2Y12 inhibitor for the remaining 11 months.
Trial: NCT05351788
Drug: SKB264
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SKB264 will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle (5mg/kg)
Trial: NCT05351788
Drug: KL-A167
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KL-A167 will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle (1200mg Q3W)
Trial: NCT05333835
Drug: HR17031 injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HR17031 injection
Trial: NCT05333835
Drug: INS068 injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INS068 injection
Trial: NCT05333835
Drug: SHR20004 injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR20004 injection
Trial: NCT05512598
Drug: HB0034
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HB0034, a single dose
Trial: NCT06361212
Drug: Ethoximod
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethoximod is a S1P1 modulator.
Trial: NCT06618573
Drug: Isoniazid/Pyridoxine
RxNorm normalized name: ISONIAZID/PYRIDOXINE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment group received isoniazid 300mg and pyridoxine 10mg/day
Trial: NCT06618573
Drug: Saccharum Lactis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group received placebo
Trial: NCT04990037
Drug: FOLFIRINOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered intravenously
Trial: NCT04932083
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: patients will be put in the sitting position and lean forward. After sterilization, Dural puncture will be performed at L4-L5 interspace or L3-L4 with a 25 gauge Quincke spinal needle.~patients will receive the local anesthetic dose of 0.5% heavy bupivacaine (12.5 mg) and 0.5 ml of fentanyl (25µg) will be added.
Trial: NCT06700395
Drug: TQB2029 injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TQB2029 for injection is a bispecific antibody targeting G Protein-Coupled Receptor, Class C, Group 5, Member D (GPRC5D) and Cluster of Differentiation 3 (CD3) . By recruiting and activating CD3 positive T cells, it induces T cells to kill malignant plasma cells expressing GPRC5D, thereby inhibiting the occurrence and development of tumors.
Trial: NCT05095077
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Identical to active IMP
Trial: NCT04800263
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be injected subcutaneously
Trial: NCT06260059
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To patients randomized to the placebo group, a placebo pill will be given
Trial: NCT05238337
Drug: [14C]-PBI-200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[14C\]-radio-labeled-PBI-200
Trial: NCT06383702
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will take placebo tablets for the duration of 14 weeks. The dosage will include 165 mg daily (for the titration and the withdraw period) and 330 mg daily for the fixed-dose period.
Trial: NCT05633407
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Receive a matching placebo during weekly infusions during a treatment period of 24 weeks.~Participants will be randomized to receive efgartigimod IV 10 mg/kg or matching placebo in a 2:1 ratio, respectively
Trial: NCT03949478
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen to be prepared in a tablet that is not distinguishable from nifedipine or placebo tablet.
Trial: NCT04967014
Drug: HIP2101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test drug
Trial: NCT04967014
Drug: RLD2101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference drug
Trial: NCT05842785
Drug: Phase II-HNSCC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The eligible subjects will receive RP2D of TSN222 via intratumoral (i.t.) injection on Days 1, 8 and 15 of every 28-day cycle until disease progression or unacceptable toxicity.
Trial: NCT05842785
Drug: Phase II-Advanced melanoma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The eligible subjects will receive RP2D of TSN222 via intratumoral (i.t.) injection on Days 1, 8 and 15 of every 28-day cycle until disease progression or unacceptable toxicity.
Trial: NCT05842785
Drug: Phase II-solid tumors or lymphomas
RxNorm normalized name: human breast tumor cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The eligible subjects will receive RP2D of TSN222 via intratumoral (i.t.) injection on Days 1, 8 and 15 of every 28-day cycle until disease progression or unacceptable toxicity.
Trial: NCT05177029
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching to Lu AG06466 will be administered per schedule specified in the arm.
Trial: NCT05470075
Drug: HR18042 tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: HR 18042 tablets 175mg and placebos match to Tramadol hydrochloride SR Tablets Dosing frequency: single dose; Route of administration: oral
Trial: NCT05470075
Drug: HR18042 tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: HR 18042 tablets 225mg and placebos match to Tramadol hydrochloride SR Tablets Dosing frequency: single dose; Route of administration: oral
Trial: NCT05470075
Drug: HR18042 tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: HR 18042 tablets 275mg and placebos match to Tramadol hydrochloride SR Tablets Dosing frequency: single dose; Route of administration: oral
Trial: NCT05470075
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: Placebos match to HR18042 tablets and Tramadol hydrochloride SR Tablets Dosing frequency: single dose; Route of administration: oral
Trial: NCT05955885
Drug: Flurbiprofen Oral Lozenge
RxNorm normalized name: flurbiprofen Oral Lozenge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This commercially available, over-the-counter lozenge manufactured by Reckitt Benckiser contains flurbiprofen as the active ingredient and is registered for the short-term treatment of sore throat associated with upper respiratory tract infections in people over the age of 12 years.
Trial: NCT05955885
Drug: Flurbiprofen 8.75 MG
RxNorm normalized name: flurbiprofen 8.75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This commercially available, over-the-counter spray manufactured by Reckitt Benckiser contains flurbiprofen as the active ingredient and is registered for the short-term treatment of sore throat associated with upper respiratory tract infections in people over the age of 12 years. It requires 3 actuations of the spray to deliver the full 8.75 dose. Here, a low dose control can be delivered by only performing 1 actuation of the spray.
Trial: NCT01861834
Drug: Omegaven 10%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with a sustained TPN requirement due to short bowel syndrome and TPN-associated liver disease that threatens progression to liver failure and death, for which the only available means of prevention at present is timely liver and/or intestinal transplant.~Omegaven 10%, 1 gram/kg, IV, every 12 hours until transplantation, or stopping TPN
Trial: NCT04898712
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo will consist of an identical capsule to over-encapsulated tranexamic acid oral tablet entirely filled with microcrystalline cellulose, and sealed.
Trial: NCT04810104
Drug: AZD0328
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active study drug
Trial: NCT04810104
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-active study drug
Trial: NCT05285592
Drug: Standard Medical Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Medical Treatment
Trial: NCT05428215
Drug: 17beta Estradiol
RxNorm normalized name: Estradiol-17beta
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will take individualized therapeutic dose of 17-beta-estradiol via sublingual and oral administration
Trial: NCT06481852
Drug: MTT with antibiotic preconditioning + placebo supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MTT will in a capsule form composed of freeze-dried, encapsulated intestinal microbiota from healthy donors. Patients will be followed at week 1, week 2, week 4, week 12, and week 24. Patient will undergo stool sample collection at baseline, week 1, week 4, and week 12, blood sample collection at baseline, week 4, and week, 12. In addition, patient will undergo an echocardiogram, six-minute walk test (6MWT) and quality of life questionnaire at baseline and at week 12.
Trial: NCT06537050
Drug: JX2105
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral capsule
Trial: NCT06537050
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral capsule
Trial: NCT04783389
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo subcutaneous (SC) injection.
Trial: NCT05217758
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, once daily, 7 days
Trial: NCT06205797
Drug: HU-045
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HU-045 is a medicine that is injected into muscles and used to improve the look of moderate to severe frown lines between the eyebrows (glabellar lines) in adults for a short period of time (temporary). It should be reconstituted with sterile, preservative-free 0.9% saline before use.~White powder~Other Names:~IncobotulinumtoxinA